- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02474485
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR (AbsorbISR)
Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis
Study Overview
Status
Conditions
Detailed Description
This is randomized-controlled trial of Absorb® Bioresorbable Vascular Scaffold (BVS) vs. Sequent Please® drug coated balloon in an all-comers population with in-stent-restenosis (ISR). The patients will be randomized in a 1:1 fashion and the investigators intend to include 150 patients.
All patients presenting with ISR and requiring percutaneous coronary intervention will be eligible to be included in this study. This will include patients with stable angina and those presenting with acute coronary syndrome (ACS).
The primary objective of this study is to demonstrate superiority of the Absorb® bioresorbable scaffold compared to the Sequent Please® Drug Coated Balloon when treating patients with In-Stent-Restenosis regards to primary endpoint - angiographic late lumen loss at 9 month follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Luzern, Switzerland, 6000
- Luzernen Kantonsspital, Spitalstrasse 16
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Diagnosed with ISR requiring percutaneous coronary intervention: visual diameter stenosis > 70 % and/or Fractional Flow Reserve < 0.81 and/or non-invasive testing demonstrating ischemia. This real-life population with in-stent restenosis beside typical stable patients with ISR includes ACS patients with thrombus containing lesions, patients with multivessel disease, patients with ISR in non-infarct related artery, with ISR in bare metal stent (BMS), drug eluting stent (DES) or bioresorbable vascular scaffold (BVS), ISR in lesion previously treated by plain old balloon angioplasty (POBA), drug eluting balloon (DEB) or additional stent implantation.
- Double anti-platelet therapy for the duration of at least 12 months is considered possible at the time of intervention
Exclusion Criteria:
- The participant may not enter the study if the interventionist has doubts that he is not able to deliver and implant the Absorb scaffold (e.g. highly calcified lesions).
- Patients who have any contraindications for using DEB (SeQent Please) or BVS (Absorb) specified in instructions for use are not able to participate in this study.
- Women with childbearing potential must have a negative result of pregnancy test and they must use an effective contraception method for at least 12 months after study procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BVS - Absorb
BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:
|
Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
Control coronary angiography will be performed at 9 month follow-up.
OCT visualization will be performed during index procedure and at 9 month follow-up.
Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure.
Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
|
Active Comparator: DEB - Sequent Please
In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:
|
Control coronary angiography will be performed at 9 month follow-up.
OCT visualization will be performed during index procedure and at 9 month follow-up.
Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure.
Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Angiographic late lumen loss at 9 month follow-up.
Time Frame: At 9 month follow up.
|
Angiographic late lumen loss will be compared between both study groups.
|
At 9 month follow up.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of periprocedural complications: unplanned use of GP IIb/IIIa inhibitors.
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Incidence of periprocedural complications: vessel rupture.
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Incidence of periprocedural complications: side branch occlusion.
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Incidence of periprocedural complications: peri-procedural myocardial infarction.
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Comparison of minimal luminal diameter between both groups and in specific populations (patients with acute coronary syndromes, patients with diabetes, patients with long lesions (> 25 mm)).
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Comparison of diameter stenosis between both groups and in specific populations (patients with acute coronary syndromes, patients with diabetes, patients with long lesions (> 25 mm)).
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Comparison of rate of restenosis between both groups and in specific populations (patients with acute coronary syndromes, patients with diabetes, patients with long lesions (> 25 mm)).
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Incidence of in-stent-restenosis in long-term observation.
Time Frame: During 60 month follow-up.
|
During 60 month follow-up.
|
Incidence of target lesion failure in long-term observation.
Time Frame: During 60 month follow-up.
|
During 60 month follow-up.
|
Incidence of target vessel revascularisation in long-term observation.
Time Frame: During 60 month follow-up.
|
During 60 month follow-up.
|
Incidence of stent thrombosis in long-term observation.
Time Frame: During 60 month follow-up.
|
During 60 month follow-up.
|
Occurence of stent thrombosis (defined as early, late and very late probable or definite according to ARC definition).
Time Frame: During 60 month follow-up.
|
During 60 month follow-up.
|
Cardiac and non-cardiac death in both groups.
Time Frame: During 60 month follow-up.
|
During 60 month follow-up.
|
Assessment of possibility vessel measurement and stent diameter/length choice based on these measurement in optical coherence tomography (OCT).
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Result of index procedure assessment in OCT post procedure (lumen/stent area, struts assessment, dissections, stent expansion).
Time Frame: Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
Participants will be followed for the duration of index procedure, an expected average of 1 hour.
|
OCT assessment of long-term study results (lumen/stent area, struts assessment, neointimal volume, lumen volume).
Time Frame: At 9 month follow-up.
|
At 9 month follow-up.
|
Lumen volume change between index and 9 month follow-up OCT.
Time Frame: OCT parameters change will be assessed between index hospitalization and 9 month follow-up.
|
OCT parameters change will be assessed between index hospitalization and 9 month follow-up.
|
Minimal lumen area change between index and 9 month follow-up OCT.
Time Frame: OCT parameters change will be assessed between index hospitalization and 9 month follow-up.
|
OCT parameters change will be assessed between index hospitalization and 9 month follow-up.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Florim Cuculi, Prof. dr
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AbsorbISR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on BVS Absorb implantation.
-
LMU KlinikumDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)Completed
-
Abbott Medical DevicesWithdrawn
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Coronary Disease | Cardiovascular Disease | Coronary Restenosis | Coronary Artery StenosisNetherlands, Taiwan, China, New Zealand, Singapore, France, United Kingdom, Austria, Israel, Italy, Malaysia, India, Poland, Sweden, Spain, South Africa, Canada, Australia, Japan, Argentina, Brazil, Switzerland, Belgium, Denmark, Germany
-
J.J. WykrzykowskaAbbott Medical DevicesUnknownMyocardial Infarction | Infarction | Ischemia | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Arteriosclerosis | Coronary Bifurcation Lesions | Arterial Occlusive LesionsNetherlands
-
Uppsala UniversityAbbott Medical Devices; The Medicines Company; InfraredxCompletedAcute Coronary Syndrome (ACS)Sweden
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Angina Pectoris | Ischemic Heart Disease | Coronary Artery OcclusionJapan
-
Luzerner KantonsspitalUnknown
-
University of MalayaBoston Scientific Corporation; Kurume UniversityCompletedCoronary Artery Disease
-
The University of New South WalesTerminatedIschemia | Arterial Occlusive Diseases | Peripheral Arterial Disease (PTANew Zealand, Australia, Netherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UnknownMyocardial Infarction | Coronary Artery DiseaseNetherlands